Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse

Haematologica

Volumn 90, Issue 6, 2005, Pages 861-862

  Mattei, Daniele ^a   Mordini, Nicola ^a   Taglianti, Riccardo Vigna ^a   Bruno, Benedetto ^b   Rapezzi, Davide ^a   Gallamini, Andrea ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Bortezomib; Multiple myeloma; Progression; Relapse

Indexed keywords

BORTEZOMIB; CYCLOSPORIN A; FLUDARABINE; LACTATE DEHYDROGENASE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEASOME INHIBITOR; STEROID; THALIDOMIDE;

ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CASE REPORT; CLINICAL PROTOCOL; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROPATHY; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LOW DRUG DOSE; LYMPHOCYTE TRANSFER; MALE; MULTIPLE MYELOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT FAILURE; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PYRAZINES; RECURRENCE; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 21244472624     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Besinger W, et al. Allografting with non-myeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102:3447-545.
2. Kröger N, Schwerdtferger R, Kiel M, Gottfried Sayer H, Renges H, Zabelina T, et al. Autologous bone marrow transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100:755-60.
3. Mothy M, Attal M, Marit G, Bulabois CE, Garban F, Gratecos N, et al. Thalidomide salvage treatment following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myèlome (IFM) and the Societe Française de Greffe de Moelle et Thèrapie Cellulaire (SFGM-TC). Bone Marrow Transplant 2005;35:165-9.
4. Kröger N, Shimoni A, Zagnvnaja M, Ayuk F, Lioznov M, Schieder H, et al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood 2004;104:3361-3.
5. Richardson P, Barlogie B, Berenson J, Singhal S. Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
6. Patriarca F, Prosdocimo S, Tomadini V, Vasciaveo A, Bruno B, Fanin R. Efficay of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005;90:278-9.
7. Fassas A, Shaughnessy J, Barlogie B. Cure of myeloma: hype or reality. Bone Marrow Transplant 2005;35:215-24.
8. Lee CK, Badros A, Barlogie B, Morris C, Zangari A, Fassas A, et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003;31:73-80.